Groundbreaking Study Advances Gene Therapy with Engineered Virus-Like Particles
A groundbreaking study published in ACS Nano reveals how researchers at the National Physical Laboratory, in collaboration with IBM and STFC, have developed artificial virus-like particles (virions) for targeted genetic delivery. This innovative approach promises advancements in gene therapy and personalized medicine, addressing drug delivery challenges while potentially offering new antibiotic alternatives. Learn more about the implications of this research for the future of biotechnology and healthcare.
INTEGRA Biosciences Supports HilleVax’s Norovirus Vaccine Development
INTEGRA Biosciences has awarded 50 EVOLVE manual pipettes, GRIPTIPS® pipette tips, and lab accessories to HilleVax to support its norovirus vaccine development. The prize will accelerate the vaccine candidate to licensure, aligning with INTEGRA’s commitment to advancing healthcare and laboratory technology.